IQ-AI Limited Keck Medical Centre of USC Purchases IB's Software (0876Z)
September 16 2020 - 2:00AM
UK Regulatory
TIDMIQAI
RNS Number : 0876Z
IQ-AI Limited
16 September 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
Keck Medical Center of USC Purchases Imaging Biometrics'
Software
Imaging Biometrics(R), LLC ("IB"), a subsidiary of IQ-AI Limited
(LON:IQAI), is pleased to announce that the Keck Medical Center of
USC has purchased IB Clinic for automatically generating IB's
quantitative parameter maps. The installation provides Keck Medical
Center with a processing solution that allows for standardised
brain tumour imaging across multiple sites and platforms for its
patients.
IB clinic includes the IB Neuro(TM) module, which generates
images of relative cerebral blood volume (rCBV), a magnetic
resonance imaging (MRI) method for evaluating brain tumours. As
many studies have shown, higher rCBV is correlated with more
aggressive tumours (higher tumour grade) and provides information
for diagnosis and treatment optimisation. IB Neuro's capabilities
from its inception are consistent with national consensus
recommendations for collecting and processing rCBV data as
published in Neuro-Oncology.
Unique to IB Neuro is the ability to automatically account for
variability inherent with MRI systems by translating the relative
MR intensity values to a fixed and consistent scale regardless of
scanner platform, field strength, patient, or time point.
Quantitatively assessing how a tumour is changing over time is
critical for both clinicians and their patients.
"The reliability of IB Neuro's rCBV maps empower our physicians
with confidence that we are making the right decisions for our
patients," says Mark Shiroishi, MD, Director of Neuro-Oncology
Imaging at Keck Medical Center and Chief of Pediatric
Neuroradiology at the LA County/USC Medical Center.
IB Clinic's imaging suite at Keck Medical Center includes
automated Delta T1(TM) maps, quantitative subtraction maps proven
to eliminate confounding artifacts, such as blood products, and
enable objective and rapid identification of true contrast
enhancing regions for radiologists. The two biomarkers, IB's Delta
T1 and rCBV maps, provide complementary information that aids the
diagnostic process and improves productivity.
"We are excited that Keck Medical Center has adopted our brain
tumour imaging platform. IB Clinic's quantitative output is ideal
for major cancer centers such as Keck Medical Center as it
automates and standardises care across sites, scanners, and
patients. We are equally excited for the collaborative research
relationships now established between our two organisations and
translating future developments that may result," said Michael
Schmainda, CEO of IB.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
About Keck Medicine of USC
Keck Medicine of USC is the University of Southern California's
medical enterprise, one of only two university-based medical
systems in the Los Angeles area. Keck Medicine combines academic
excellence, world-class research and state-of-the-art facilities to
provide highly specialized care for some of the most acute patients
in the country.
Its internationally renowned physicians and scientists provide
world-class patient care at Keck Hospital of USC, USC Norris Cancer
Hospital, USC Verdugo Hills Hospital and more than 80 outpatient
locations in Los Angeles, Orange, Kern, Tulare and Ventura
counties.
Keck Medical Center of USC was ranked among the top 20 hospitals
nationwide on U.S. News & World Report's 2020-21 Best Hospitals
Honor Roll and among the top 3 hospitals in Los Angeles and top 5
in California.
About Imaging Biometrics, LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRSFAFMIESSESU
(END) Dow Jones Newswires
September 16, 2020 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024